Refine your search with our Advanced Search Tool
Listing contains 128 trial(s)
Breast Cancer, Female
Lab
University of Pittsburgh Tissue Acquisition for Patients at Risk for Breast Cancer or Have Been Diagnosed with Breast Cancer: Tissue and Body Fluid Acquisition Protocol Study Number: 04-162 |
Phase I
A Phase 1 Study of Chronically-Dosed, Single-Agent ABT-888 in Patients with Either BRCA 1/2 Mutated Cancer; Platinum-Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer; or Basal-Like Breast Cancer Study Number: 08-121 |
Phase III
Phase III Evaluating the Role of Ovarian Function Suppression and Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine-Responsive Breast Cancer Study Number: 04-058 |
A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) vs. Partial Breast Irradiation (PBI) for Women with Stage 0, 1 or II Breast Cancer Study Number: B-39 |
Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer Study Number: 06-031 |
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial (ECOG PACCT-1) Study Number: 06-082 |
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer Study Number: B-42 |
A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel When Administered Before AC With or Without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with Each of the Regimens (NSABP) Study Number: B-40 |
The Effect of Bisphosphonate on Bone Mass and Bone Turnover in Elderly, Postmenopausal Women with Breast Cancer Following Initiation of Aromatase Inhibitor Therapy (REBBeCA II Study) Study Number: 06-138 |
A Randomized Phase III Trial of Neoadjuvant Therapy for Patients with Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered with Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response (NSABP B-41) Study Number: B-41 |
A Phase III, Randomized, Double-Blind, Placebo Controlled Clinical Trial to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated Her2-Positive Metastatic Breast Cancer (TOC4129g/WO20698) Study Number: 07-135 |
A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab (BETH B-44-I) Study Number: B-44-I |
A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy NSABP B-43 Study Number: B-43 |
A Randomized Trial of IxempraTM vs. Taxol in Adjuvant Therapy of Triple-Negative Breast Cancer BRE 145 (TITAN) Study Number: 09-014 |
A Randomized Phase III Trial to Test the Strategy of Changing Therapy Versus Maintaining Therapy for Metastatic Breast Cancer Patients who Have Elevated Circulating Tumor Cell Levels at First Follow-Up Assessment (SWOG 0500) Study Number: 09-023 |
Pilot
The ACT Intervention to Reduce Breast Cancer Treatment Disparity Study Number: 06-096 |
Quality of Life Study
Pain, Distress and Mammography Use in Breast Cancer Patients Study Number: 08-058 |
